Comment from CSNK2A1 Foundation

Summary: The CSNK2A1 Foundation, an advocacy organization, supports the FDA's Request for Information regarding drug repurposing for unmet medical needs. They argue that the FDA should recognize early signals from preclinical and clinical studies as justification for further study, prioritization, and evaluation, especially for rare diseases where clinical data is limited.